Loading clinical trials...

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors. | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.

NCT07040943•West China Hospital

View on ClinicalTrials.gov

Summary

This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.

Detailed Description

Cancer is a leading global cause of death, with advanced cases posing significant treatment challenges due to low efficacy and severe side effects. Gene therapy, especially mRNA-based immunogene therapy, offers promise. IL-22 promotes tumor progression, and its antagonist, IL-22BP, can inhibit tumor growth. Patients with refractory, metastatic solid tumors unresponsive to second-line therapy lack viable options. This study aims to establish a novel IL-22BP-based mRNA treatment for advanced cancers.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female patients: aged ≥ 18 years old and ≤ 70 years old;
•2. Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent/metastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.);
•3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1;
•4. Expected survival time ≥ 3 months;
•5. More than 28 days since the last chemotherapy/radiotherapy/surgery;
•6. More than 6 weeks since the last use of nitrosoureas or mitomycin C;
•7. Main organ functions are in good condition;
•8. Sign a written informed consent form.

Exclusion Criteria

•1. Have participated in other drug clinical trials within 4 weeks;
•2. The tumor is located close to major blood vessels or the trachea;
•3. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of NYHA class II or above, unstable angina pectoris, having had a myocardial infarction within 1 year, and having clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.
•4. For female subjects: pregnant or lactating women.
•5. Patients have active tuberculosis, bacterial or fungal infections (≥ grade 2 of NCI-CTCAE 5.0); have active HIV infection, active HBV infection, or HCV infection.
•6. Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders;
•7. Subjects have any active autoimmune diseases or a history of autoimmune diseases (such as, but not limited to: uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or those whose asthma in childhood has been completely relieved and who do not require any intervention in adulthood can be included; subjects with asthma that requires bronchodilators for medical intervention cannot be included).
•8. Subjects are currently receiving immunosuppressive treatment.
•9. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcoholism or drug use.
•10. Known to be allergic, hypersensitive, or intolerant to the studied IL-22BP (including any excipients). Have a severe allergy history to any drugs, foods, or vaccines in the past, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrotizing reaction (Arthus reaction), etc.
+2 more criteria

Locations (2)

Department of Radiation Oncology

Chengdu, Sichuan, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Key Dates

Start Date

June 29, 2025

Primary Completion Date

July 1, 2026

Completion Date

July 1, 2026

Last Updated

July 1, 2025

Enrollment

ESTIMATED participants

Conditions

Refractory Malignant Solid TumorsmRNA VaccineInterleukin

Interventions

IL-22BP

BIOLOGICAL

Contacts

Xingchen Peng

CONTACT

18980606753 pxx2014@163.com

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye

NCT07396441

Juvenile Open Angle GlaucomaDry Eye Disease (DED)+3 more

View study

RECRUITING

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

NCT07017868

Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Inclusion Criteria

Exclusion Criteria

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

The Maintenance Treatment of "ITIVA" in AML Patients

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis